Rove Hotels Unveils the Only On-Site Hotel at Expo 2020 Dubai
27.10.2020 13:17:00 EET | Business Wire | Press release
With Expo 2020 Dubai now less than a year away, the eyes of the world are back on this much-awaited event, as it gears up to help shape the future. A homegrown hotel brand that can be found at the heart of communities across Dubai – Rove Hotels made the very special announcement that it will be the only hotel at Expo 2020 Dubai, which will be taking place from 1st October 2021 to 31st March 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005569/en/
For those who Rove: Rove Expo 2020, the only on-site hotel at Expo 2020 Dubai, adjacent to Al Wasl Plaza - (Photo : AETOSWire)
A gateway to inspiring experiences of culture, innovation and human excellence at Expo 2020, the Rove Expo 2020 hotel – part of the Rove brand – will feature 312 king, twin and accessible Rover Rooms, as well as 19 Rover suites. Furthermore, the only hotel at Expo 2020 will boast several F&B outlets, including The Daily, a grab & go Rove Café and The Bar, along with a rooftop swimming pool and sundeck overlooking the Al Wasl Plaza, 100% sustainable in-room amenities, a 24-hour gym, prayer rooms, and more.
Marjan Faraidooni, Chief Pavilions and Exhibitions Officer at Expo 2020 Dubai, said, “This is a significant step forward in the development of the Expo 2020 site. An on-site hotel is a great addition to the world-class facilities we are creating to welcome people from all around the world to experience this once-in-a-lifetime event.”
“Rove Expo 2020 will remain as a permanent modern hospitality offering at District 2020, which will evolve into a smart human-centric community as the future of Expo 2020 Dubai. It will support District 2020’s aim to create a mixed-use development and an innovation-driven urban destination that caters to the needs of its future workers, residents and visitors through its diverse community offering,” she added.
The Rove team is even more excited and determined than ever to cater to the diverse needs of visitors from all over the world as the one and only hotel destination inside Expo 2020.
“This exciting hotel will no doubt boost the already huge appeal of such a historical and major event for the UAE, and offer Expo 2020 visitors a new and innovative type of hospitality option at the heart of the Expo site,” said Mr. Ahmad Thani Rashed Al Matrooshi, Board Director of Rove Hotels LLC.
For more information, visit https://www.rovehotels.com/hotel/rove-expo-2020/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005569/en/
Contact information
Katch International
Dhara Bhatia,
Engagement Consultant, +971567944126
dhara@katchthis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 15:00:00 EEST | Press release
Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have faced two critical dining pain points: [Pain Point 1] The Information Gap: Most available resources are tailored for tourists, making it difficult to find the true loc
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 15:00:00 EEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 14:00:00 EEST | Press release
In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football trading cards from 2031 onward. All products will be designed and developed through Fanatics Collectibles and produced under the Topps brand. As a part of the deal, Fanatics will bring the magic to young people in every region of the world and support youth football globally by distributing more than $150 million in collect
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release
The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom